J&J and Legend’s Carvykti receives EC approval to treat relapsed and refractory multiple myeloma
The BCMA-targeted therapy is the first to receive approval in Europe for RRMM patients as early as first relapse
Read More
Apr 25, 2024 | News, Regulatory
The BCMA-targeted therapy is the first to receive approval in Europe for RRMM patients as early as first relapse
Read MoreApr 25, 2024 | News, Regulatory
Up to 40% of patients who have undergone definitive prostate cancer treatment will experience biochemical recurrence within ten years
Read MoreThe company combines machine learning, data generation and therapeutic product development
Read MoreApr 25, 2024 | News, Regulatory
The incidence of neuroendocrine tumours has increased over the past several decades
Read MoreApr 25, 2024 | News, Regulatory
The type 2 RAF inhibitor is the first and only one approved in the US to treat this patient population
Read MoreApr 24, 2024 | News, Regulatory
Gliomas are the most common type of brain cancer in paediatric patients
Read MoreThe deal includes an MRGPRX2 antagonist with the potential to treat multiple mast cell-mediated diseases
Read MoreApr 24, 2024 | News, Regulatory
The factor D inhibitor has been authorised for use alongside the company’s complement C5 inhibitors
Read MoreApr 24, 2024 | News, Regulatory
NMIBC accounts for up to 80% of bladder cancer cases, the tenth most commonly diagnosed cancer globally
Read MoreAD is the most common form of dementia, which affects around 55 million people globally
Read MoreApr 23, 2024 | News, Regulatory
Antimicrobial resistance has been declared by WHO as one of the top ten threats to global health
Read MoreApr 23, 2024 | News, Regulatory
The regulator’s decision marks Bimzelx’s fourth approved indication within the EU
Read MoreAccount Specialist - Respiratory - Kent & Medway
National Field Trainer - Oncology - UK Wide
Integrated Care Specialist - North & West Yorkshire
Hospital Specialist - East Midlands